Reckitt Shares Climb on Favorable U.S. Baby Formula Verdict and J.P. Morgan Upgrade

Shares of Reckitt Benckiser Group (LSE:RKT) surged on Tuesday, climbing 4.3% after the company secured a significant legal victory in the U.S. and received a favorable rating change from J.P. Morgan. The dual catalysts helped alleviate investor concerns that have weighed on the stock.

Favorable Verdict in Key Lawsuit

A U.S. jury delivered a unanimous verdict in favor of Reckitt's Mead Johnson subsidiary in a case concerning its Enfamil preterm baby formula. The lawsuit, heard in the U.S. District Court for the Northern District of Illinois, alleged the product caused necrotizing enterocolitis (NEC), a serious intestinal disease.

This case was the first bellwether trial in the federal multidistrict litigation against Mead Johnson. Following the verdict, Reckitt stated that there are currently no outstanding jury verdicts against its unit in the broader NEC litigation, marking a crucial win for the company.

Analyst Upgrade Boosts Sentiment

Ad

Adding to the positive momentum, analysts at J.P. Morgan upgraded Reckitt's stock to "overweight" from a "neutral" rating. The investment bank suggested the legal victory could allow investors to refocus on the value of the company's core business.

J.P. Morgan analyst Celine Pannuti noted that prospects for resolving the NEC litigation are rising, which could remove a significant overhang on the stock. "The elimination of the overhang for Reckitt should allow the market to refocus on the core valuation," Pannuti commented, according to the report.

Context for Investors

The numerous lawsuits related to its infant formula products have been a major headwind for Reckitt's share price in recent months. The legal uncertainty has prompted the company to explore strategic options for its baby formula business as it seeks to concentrate on its core brands.